27 related articles for article (PubMed ID: 10091218)
1. Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics.
Le BT; Raguraman P; Kosbar TR; Fletcher S; Wilton SD; Veedu RN
Mol Ther Nucleic Acids; 2019 Mar; 14():142-157. PubMed ID: 30594893
[TBL] [Abstract][Full Text] [Related]
2. Treatment of prostate and breast tumors employing mono- and bi-specific antisense oligonucleotides targeting apoptosis inhibitory proteins clusterin and bcl-2.
Rubenstein M; Tsui P; Guinan P
Med Oncol; 2010 Sep; 27(3):592-9. PubMed ID: 19533419
[TBL] [Abstract][Full Text] [Related]
3. Synergistic effects of combination therapy employing antisense oligonucleotides with traditional chemotherapeutics in the PC-3 prostate cancer model.
Tsui P; Rubenstein M; Guinan P
Med Oncol; 2004; 21(4):339-48. PubMed ID: 15579918
[TBL] [Abstract][Full Text] [Related]
4. Treatment of the T98G glioblastoma cell line with antisense oligonucleotides directed toward mRNA encoding transforming growth factor-alpha and the epidermal growth factor receptor.
Rubenstein M; Glick R; Lichtor T; Mirochnik Y; Chou P; Guinan P
Med Oncol; 2001; 18(2):121-30. PubMed ID: 11778757
[TBL] [Abstract][Full Text] [Related]
5. Chemosensitization by antisense oligonucleotides targeting MDM2.
Bianco R; Ciardiello F; Tortora G
Curr Cancer Drug Targets; 2005 Feb; 5(1):51-6. PubMed ID: 15720189
[TBL] [Abstract][Full Text] [Related]
6. Bispecific antisense oligonucleotides having binding sites directed against an autocrine regulated growth pathway and bcl-2 for the treatment of prostate tumors.
Rubenstein M; Tsui P; Guinan P
Med Oncol; 2007; 24(2):189-96. PubMed ID: 17848743
[TBL] [Abstract][Full Text] [Related]
7. Backbone modification alters the efficacy of antisense oligonucleotides directed against mRNA encoding either TGF-alpha or EGFR in the treatment of prostate cancer cell lines.
Rubenstein M; Slobodskoy L; Mirochnik Y; Guinan P
Methods Find Exp Clin Pharmacol; 2002 Dec; 24(10):649-52. PubMed ID: 12616956
[TBL] [Abstract][Full Text] [Related]
8. Construction of a bispecific antisense oligonucleotide containing multiple binding sites for the treatment of hormone insensitive prostate tumors.
Rubenstein M; Tsui P; Guinan P
Med Hypotheses; 2005; 65(5):905-7. PubMed ID: 16023790
[TBL] [Abstract][Full Text] [Related]
9. Treatment of MCF-7 breast cancer cells employing mono- and bispecific antisense oligonucleotides having binding specificity toward proteins associated with autocrine regulated growth and BCL-2.
Rubenstein M; Tsui P; Guinan P
Med Oncol; 2008; 25(2):182-6. PubMed ID: 17972023
[TBL] [Abstract][Full Text] [Related]
10. Multigene targeting of signal transduction pathways for the treatment of breast and prostate tumors: comparison between combination therapies employing bispecific oligonucleotides with either Rapamycin or Paclitaxel.
Rubenstein M; Tsui P; Guinan P
Med Oncol; 2009; 26(2):124-30. PubMed ID: 18686047
[TBL] [Abstract][Full Text] [Related]
11. Growth factor deprivation therapy of hormone insensitive prostate and breast cancers utilizing antisense oligonucleotides.
Rubenstein M; Mirochnik Y; Chou P; Guinan P
Methods Find Exp Clin Pharmacol; 1998 Dec; 20(10):825-31. PubMed ID: 10091218
[TBL] [Abstract][Full Text] [Related]
12. Growth factors and their receptors: new targets for prostate cancer therapy.
Barton J; Blackledge G; Wakeling A
Urology; 2001 Aug; 58(2 Suppl 1):114-22. PubMed ID: 11502465
[TBL] [Abstract][Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]